Chromatographia

, 67:701 | Cite as

An Improved Narrow-Bore LC Method for Quantification of Alfuzosin in Pharmaceutical Formulations

  • Nikolaos Aerakis
  • Ariadni Vonaparti
  • Irene Panderi
Original

Abstract

A simple rapid and stability-indicating LC method using a narrow-bore column has been developed, fully validated, and applied to the quantification of alfuzosin in pharmaceutical formulations. Chromatography was achieved isocratically on a narrow-bore, 5-μm particle size, C8 analytical column. The mobile phase was a 35:65 (v/v) 0.0125 m ammonium formate–acetonitrile at a flow rate of 0.35 mL min−1. Detection was by UV absorption at 245 nm. Evaluation over the range 200–800 ng mL−1 revealed linearity was good. Limits of detection and quantification for alfuzosin were 22.9 and 69.5 ng mL−1, respectively. Intra-day and inter-day RSD were less than 6.4%, and the relative percentage error was less than −1.7% (n = 5). Accelerated degradation performed under different stress conditions including oxidation, hydrolysis, and heat, proved the selectivity of the procedure. The method was successfully used for quality-control and content-uniformity testing of commercial tablets.

Keywords

Column liquid chromatography Alfuzosin Pharmaceutical dosage forms Stability-indicating method Validation 

References

  1. 1.
    Wilde MI, Fitton A, McTavish D (1993) Drugs 45:410–429CrossRefGoogle Scholar
  2. 2.
    Haddouche A, Boisset M, Thenot JP, Desjeux JF (1996) Eur J Pharm Sci 4:259–266CrossRefGoogle Scholar
  3. 3.
    Leferve-Borg F, O’Connor SE, Schoemaker H, Hicks PE, Lechaire J, Gautier E, Pierre F, Pimoule C, Manoury P, Langer SZ (1993) Br J Pharmacol 109:1282–1289Google Scholar
  4. 4.
    McVary KT (2007) Clin Ther 29:387–398CrossRefGoogle Scholar
  5. 5.
    De Nunzio C, Franco G, Leonardo C, Trucchi A, Tubaro A, Laurenti C (2005) Clin Drug Invest 25:359–365CrossRefGoogle Scholar
  6. 6.
    Resnick MI, Roehrborn CG (2007) Prost Cancer Prost Dis 10:155–159CrossRefGoogle Scholar
  7. 7.
    Zuban ON, Iagafarova RK, Vinogradova TI (2006) Urologiia 45:37–39CrossRefGoogle Scholar
  8. 8.
    Palit V, Shah T, Biyani CS, Elmasry Y, Sarkar R, Flannigan GM, Puri R (2005) Int Urol Nephrol 37:507–510CrossRefGoogle Scholar
  9. 9.
    Guinebault P, Broquaire M, Colafranceschi C, Thenot JP (1986) J Chromatogr 353:361–369CrossRefGoogle Scholar
  10. 10.
    Krstulovic AM, Vende JL (1989) Chirality 1:243–245CrossRefGoogle Scholar
  11. 11.
    Carlucci G, Di Giuseppe E, Mazzeo P (1994) J Liq Chromatogr 17:3989–3987CrossRefGoogle Scholar
  12. 12.
    Rouchouse A, Manoha M, Durand A, Thenot JP (1990) J Chromatogr 506:601–610CrossRefGoogle Scholar
  13. 13.
    Haddouche A, Boisset M, Thénot JP, Desjeux JF (1996) Eur J Pharm Sci 4:259–266CrossRefGoogle Scholar
  14. 14.
    Wiesner JL, Sutherland FCW, Van Essen GH, Hundt HKL, Swart KJ, Hundt AF (2003) J Chromatogr B 788:361–368CrossRefGoogle Scholar
  15. 15.
    Uslu B (2002) Electroanalysis 14:866–870CrossRefGoogle Scholar
  16. 16.
    Rao RN, Nagaraju D, Jena N, Kumaraswamy G (2006) J Sep Sci 29:2303–2309CrossRefGoogle Scholar
  17. 17.
    Fayed AS, Shehata MAA, Hassan NY, El-Weshahy SA (2006) J Sep Sci 29:2716–2724CrossRefGoogle Scholar
  18. 18.
    Krishna MV, Sankar DG (2007) E J Chem 4:397–407Google Scholar
  19. 19.
    Neue UD (1997) HPLC columns—theory technology and practice. Wiley, New York, pp 49–53Google Scholar
  20. 20.
    Panderi I, Parissi-Poulou M (1999) J Pharm Biomed Anal 21:1017–1024CrossRefGoogle Scholar
  21. 21.
    ICH (1996) International conference on harmonization, validation of analytical procedures: methodology Q2B, FDA, USAGoogle Scholar
  22. 22.
    ICH (2003) Topic Q1F, November 2003; http://www.ich.org/LOB/media/MEDIA419.pdf

Copyright information

© Friedr. Vieweg & Sohn Verlag/GWV Fachverlage GmbH 2008

Authors and Affiliations

  • Nikolaos Aerakis
    • 1
  • Ariadni Vonaparti
    • 1
  • Irene Panderi
    • 1
  1. 1.School of Pharmacy, Department of Pharmaceutical ChemistryUniversity of AthensAthensGreece

Personalised recommendations